Abstract Background. Despite technological advances clinical differences in treatment modalities are based on differences in the clearance of middle molecules or in dialysis equipment and modalities, the survival, on biocompatibility, or, more generally, on the increasmorbidity and quality of life of uraemic patients underingly recognized clinical importance of high-flux treatgoing regular haemodialysis treatment are still severely ments, and the possible interaction between membrane affected by acute intradialysis and long-term comflux and biocompatibility. plications, possibly related to the treatment itself. Convective treatment modalities, such as haemodiafiltration and haemofiltration, are thought to be further improvements over standard diffusive Introduction haemodialysis. Moreover, several of the pathways activated in patients during dialysis have the potential In recent years, technological innovations in dialysis to produce many side-effects. These occur three times equipment and new modalities have improved the a week, and are particularly intense in patients dialysed quality of dialysis treatment. However, a number of with so-called 'bio-incompatible' membranes. Thus the acute complications or symptoms, such as intradialysis biocompatibility of dialysis membranes is increasingly hypotension, muscle cramps, headache, nausea, prurrecognized as one of the main factors in the improve-itus, fatigue and postdialysis lack of energy have been ment of dialysis treatment.
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attributed not only to the intermittent and/or insuffiMethods. The main clinical studies to date are cient depuration and to the dialysate composition reviewed to highlight the clinical effects of different (water and solutes), but also to the type of modality treatment modalities and membranes on the most (diffusive treatments) and the type of dialysis memimportant acute and long-term haemodialysis-related brane used (so-called bio-incompatibles). complications.
In fact, several of the pathways activated in patients Results. Epidemiological studies suggest that semisyn-during dialysis have the potential to produce many thetic and synthetic membranes may reduce morbidity side-effects. It is important to remember that compleand mortality in dialysis patients. Despite the proven ment and cell activation occurs three times a week biological superiority of biocompatible membranes, we over a period of years, and is particularly intense in lack definitive evidence that thrice-weekly complement patients dialysed using 'bio-incompatible' membranes. and cell activation over a period of years is detrimental Thus survival, morbidity and the quality of life of to patients, because the results of prospective random-uraemic patients undergoing regular haemodialysis ized studies are conflicting. However, it is important treatment are still severely affected by acute intrato remember that factors other than the dialysis mem-dialysis and long-term complications, possibly related to the treatment itself. brane could influence the 'biocompatibility' of dialysis, Cardiovascular instability is certainly the most including the dialysate, dialyser geometry, the distribuimportant acute haemodialysis-related complication tion of blood in the dialyser, reuse, the sterilizant and (and is possibly also, at least partly, responsible for materials used in reprocessing.
the deterioration in residual renal function) and malConclusions. Further large-scale prospective and rannutrition (possibly cause or consequence of infections), domized trials with a long follow-up are needed in b 2 -microglobulin deposition (with consequent dialysisorder to better clarify the clinical effect of different associated amyloidosis [1] ), accelerated atherosclerosis treatment modalities on the morbidity and mortality and alterations in immunodefence (with consequent of patients on chronic renal replacement therapy. In infections and cancers) are possibly the most important particular, it must be clarified whether the possible long-term complications. Therefore, convective treatments and the biocompatibility of dialysis membranes Correspondence and offprint requests to: Professor Francesco are increasingly recognized as the main factors in the However, it is important to remember that factors extracorporeal substitution programmes, despite technological advances (monitors with ultrafiltration conother than the dialysis membrane could influence the biocompatibility of dialysis, including the dialysate, trol, supplied bicarbonate dialysate) and convective strategies. Although its pathogenesis is multifactorial, dialyser geometry, the distribution of blood in the dialyser, reuse, and the sterilizants and materials used growing importance is ascribed to the progressive increase in the median age of patients beginning in reprocessing.
Moreover it must be clarified whether these improve-haemodialysis therapy, the prolonged survival of haemodialysis patients and the consequent increase in ments are based only on the biocompatibility of the membranes used normally in these convective treat-dialysis median age and cardiovascular risk factors [5] .
Another important factor is the tendency to shorten ments, or on differences in the clearance of middle molecules, or more generally on the increasingly recog-dialysis treatment time by means of increased blood flow rate, larger dialyser surface and greater ultrafiltranized clinical importance of high-flux treatments, and the possible interaction between biocompatibility and tion rate in order to reach adequate solute and fluid removal. The importance of adequate sodium removal membrane flux.
Although the problem is clinically very important, in improving intradialysis cardiovascular stability is well known. The introduction of highly permeable few prospective, randomized, controlled and adequately sized trials have addressed the clinical effects synthetic membranes into routine clinical practice has made the whole issue even more complex. They differ of different dialysis membranes and technologies on the morbidity and mortality of patients on substitutive from conventional cellulose membranes because of their minimal inflammatory-type contact reactions with treatment, to verify in vivo the short-and long-term benefit reported in vitro.
blood and also because they have large pores, which provide better convective transport and the removal In the few studies comparing two different modalities or membranes, many technical aspects (the prescribed of mid-sized and large molecules. As a consequence, the treatment strategies in which these types of and delivered dialysis dosage, dialysis time, dialysis machine with or without automatically controlled membrane are used, such as high-flux haemodialysis, haemodiafiltration and haemofiltration, are considered ultrafiltration, water quality, realized electrolyte and acid-base balances, thermal balance, convection/ to be more biocompatible than haemodialysis.
The lower intradialysis hypotension rates reported diffusion ratio), drugs employed (erythropoietin, antihypertension therapy) and many confounders difficult for haemofiltration and haemodiafiltration may be due, at least in part, to the fact that they generally remove to evaluate, such as patient expectation of the new method, and also the motivation and the belief of the less sodium than haemodialysis (at least given the present use of dialysate and reinfusate sodium concenteam (physicians and nurses) regarding a new treatment strategy, were either different or not evaluated. tration), or to their different effects on peripheral resistance compared with haemodialysis, or to the fact Thus, we should be very careful when evaluating the results of uncontrolled retrospective studies.
that these treatments are usually performed using biocompatible membranes. In contrast, there is the In order to evaluate the potential benefits of the flux (convective treatments: high-flux dialysis, haemo-possibility that the recognized superiority of biocompatible membranes on blood-membrane interaction diafiltration, haemofiltration) and/or the biocompatibility of membranes, overall in terms of morbidity and may be counterbalanced by blood-membrane-dialysate interactions. In fact, highly permeable membranes mortality, we have to take into account acute effects on the cardiovascular stability, the preservation of have large pores, therefore a high quality of dialysate is needed in order to prevent pyrogen back-transport residual renal function, nutritional aspects, infection, anaemia and the long-term effect on b 2 -microglobulin affecting cardiovascular stability. The main prospective clinical studies on the effect accumulation and deposition and subsequent amyloidosis. The potential 'renoprotective' effect of biocom-of different membranes on intradialysis cardiovascular stability are summarized in Table 1 . patibility possibly improving acute renal failure recovery and, along with the reduction of infection Chanard et al. [6 ] reported that the incidence of hypotension, vomiting, cramps and headaches was less (fatal sepsis), possibly affecting the survival of patients with acute renal failure, is beyond the scope of this for patients dialysed using the AN69 membrane.
However, there was a lack of randomization and study. This topic has been discussed thoroughly in a recent review [4] from which one should conclude that, patients in the control group (cellulose membrane) did not use machines with automatically controlled to date, an unequivocal detrimental effect of bioincompatible membranes on the course and outcome ultrafiltration.
Skroeder et al. [7] performed a prospective, randomof acute renal failure remains controversial.
ized, cross-over study on 23 patients, undergoing 12 different bicarbonate haemodialysis sessions using
Cardiovascular stability
cuprophane, hemophan or polyamide membranes for short (2 h) and long (4 h) treatments, with small or large membrane areas. Subjective and objective Cardiovascular instability during haemodialysis treatment is an important clinical problem that still affects symptoms were registered during haemodialysis and 12 and 36 h thereafter. The authors did not find the a large percentage of uraemic patients undergoing aIn cross-over studies the number of patients must be doubled to compare them with the number of patients of parallel studies (with two groups). bCu, cuprophan; PAN, polyacrylonitrile; PA, polyamide; lf-PS, low-flux polysulfone; hf-PS, high-flux polysulfone.
bio-incompatibility of the membrane to be a significant (HfPS-HDF ). Eligible patients were randomized to one of two or four treatments. Careful handling of cause of subjective or objective symptoms during haemodialysis.
dialysate was recommended in order to assure its high quality and prevent pyrogen back-transport affecting The 'Bergamo Collaborative Dialysis Group' [8] carried out a large multicentre trial designed to clarify the study results. The sample size was estimated on the basis of the expected difference in dialysis treatment the intradialysis well-being of the patients. The study was homogeneous with regard to clinical conditions. tolerance (an 18% reduction in symptomatic treatment, calculated as 30% of the dialysis session) only for the Patients were dialysed using membranes with a surface area of 1 m2 and were randomly assigned to use either two groups treated with cuprophane and low-flux polysulfone bicarbonate dialysis. For a type I (a) error cuprophane or polysulfone membranes. No differences were found in the intradialysis symptoms between the of <0.05 and a power (1-b) of 0.80 and assuming a drop-out rate of 30%, 115 patients needed to be two dialysis membranes.
Collins et al. [9] performed a randomized prospect-enrolled into each group. A total of 380 patients were enrolled and followed up for 24 months. Treatment ive, cross-over study to assess whether patients dialysed with polyacrylonitrile (PAN or AN69) have fewer tolerance, evaluated as the sum of the monthly number of dialysis sessions with hypotension, was 1.9±2.8 intradialysis hypotensions and acute symptoms than patients dialysed with a cuprophane membrane. The sessions/month for the cuprophan group and 2.61±3.47 for the low-flux polysulfone group during authors did not find any significant difference concerning intradialysis hypotension during the short the run-in phase (P=n.s.). The behaviour of this endpoint during the 24-month follow-up was not significfollow-up (3 months with each membrane). The authors stressed the inadequate statistical power of the antly different between bicarbonate dialysis with cuprophan (132 patients) or with low-flux polysulfone (147 study: only 35 patients were analysed (17 with polyacrylonitrile and 18 with cuprophane) vs the 236 patients patients) or among the four dialysis methods under evaluation. Thus, the incidence of intradialysis hyponeeded to reduce the type II statistical error.
Locatelli et al. [10] performed a prospective random-tension in the population as a whole was less than expected, possibly because of a selection bias and/or ized multicentre trial comparing, under similar conditions of convective transport and permeability, good medical care. Therefore, the authors did not find that convection and/or membrane biocompatibility treatments which differed only in terms of the clinical structures of the membranes themselves. The primary was important in improving cardiovascular stability during dialysis, mainly because it is very difficult to aim of the study was to evaluate whether, using bicarbonate dialysis, the polysulfone membrane offers find any differences in the percentage incidence of intradialysis hypotension between membranes and any advantages, in terms of treatment tolerance, nutritional parameters and pre-treatment b 2 -microglobulin treatment modalities if the incidence is low. Altieri et al. [11] performed a prospective nonlevels, over the traditional cuprophane membrane. A secondary aim was to assess whether the use of more randomized study in 23 patients comparing on-line predilution bicarbonate haemofiltration with ultrapure sophisticated methods, consisting of a biocompatible synthetic membrane (polysulfone) with different high-flux dialysis using a polyamide membrane. The adequacy of treatment was equilibrated Kt/V values hydraulic permeability (high-flux haemodialysis and haemodiafiltration), offers any further advantages. of 1.41 for HD and 1.08 for HF. The number of hypotensive episodes was 1.78±2.8 per patient per Seventy-one centres took part in this prospective, centrally randomized, controlled trial and were stratified month during HD vs 1.17±3.1 during HF (P=0.003) and the number of hypertensive episodes was 1.28±2.8 according to the availability of only the first two or all four of the following techniques: cuprophane bicarbon-during HD vs 0.42±0.8 during HF (P=0.04). The incidences of arrythmia, muscular cramps and headate haemodialysis (CU-HD), low-flux polysulfone bicarbonate haemodialyis (LfPS-HD), high-flux poly-ache were significantly less frequent during HF.
Taken together, the results of these studies do sulfone bicarbonate haemodialysis (HfPS-HD) and high-flux polysulfone bicarbonate haemodiafiltration not support the hypothesis that membrane biocom-
that future trials should involve a sicker patient (AN69) [19] . One possible explanation could be the population with a higher prevalence of intradialysis removal of higher molecular mass uraemic toxins, thus hypotension in order to achieve statistical power.
increasing the well-being of the patients and, consequently, their appetite; the increased protein and calorie intake could increase the serum albumin level,
Residual renal function
thus possibly decreasing morbidity and mortality. Moreover, dialysis with cellulose membranes promotes Patients with residual renal function may have lower or exacerbates a chronic catabolic state, leading to dietary restriction and shorter dialysis treatment times. protein wasting and malnutrition. Preservation of residual renal function may also conParker et al.
[20] designed a trial to evaluate, in 143 tribute significantly to the removal of b 2 -microglobulin, patients, the relationship between prescribed dialysis thus reducing the risk of b 2 -microglobulin-related dosage, protein catabolic rate, morbidity and mortalamyloidosis and possibly reducing the loss of produc-ity, and biocompatibility of the dialysis. The authors tion of calcitriol and erythropoietin.
found an increase in estimated body weight (~4 kg) The suggested relationship between the use of differ-and an increase in albumin plasma concentration ent dialysis membranes and the rate of decline in renal (~0.35 mg/dl ) in patients treated for 18 months with function [12] has not yet been confirmed. a low-flux polymethylmetacrilate membrane. It is Caramelo et al. [13] did not find any difference important to stress that these results have been between cuprophane and polysulfone or polyacrylo-obtained in spite the fact that Kt/V for the biocompatnitrile membranes. However, the number of patients ible membrane was 1.24, significantly less than the enrolled in this study was rather small (13 and nine Kt/V of the bio-incompatible membrane group of 1.37. respectively) and the follow-up was for only 9 months. However, baseline plasma albumin levels of the Hakim et al. [14] , analysing the effect on plasma b 2 -patients involved in this study (all at the start of renal microglobulin, found that the use of biocompatible replacement therapy) were quite low (3.5 g/dl ) and the membranes ( low-flux polymethylmetacrilate) was asso-presence of smouldering overhydratation in patients ciated with no significant difference in residual renal treated with biocompatible membranes cannot be function during the 18-month follow-up period com-excluded. Moreover, the very high number of droppared with the use of bio-incompatible membrane.
outs (due to treatment inadequacy) in the group of Schiffl et al. [15] reported the results of a prospective, patients on the biocompatible membrane (72%) comrandomized, small trial involving 20 normotensive pared with those on the bio-incompatible membrane patients. After 1 year of observation the residual renal (46%) should be taken into account in evaluating the function, estimated on the basis of creatinine clearance results of Parker et al.'s study. and daily urine volume, was twice as high in patients Locatelli et al. [10] did not find a correlation between treated with high-flux polysulfone than in those treated Kt/V and protein catabolic rate and this did not with cellulosic membranes (P<0.05).
depend on the different membrane biocompatibility or McCarthy et al. [16 ] performed a retrospective study fluxes used. One possible reason for this lack of correlausing polysulfone and cellulose acetate membranes, tion may be the high levels of Kt/V recorded in the comparing 50 consecutive patients with residual renal study: given the curvilinear relationship between PCR function and found that patients with parenchimal and Kt/V, the studied patients probably fall into the renal disease (glomerulonephritis or nephrosclerosis) plateau region where the correlation between efficiency showed markedly better retention of residual renal and nutrition is lost. One of the inclusion criteria in function with the polysulfone than with the cellulose this study was a protein catabolic rate of no less than acetate membrane.
1g/kg/day, moreover the plasma albumin was well preserved in the population as a whole at baseline (4.2±0.4 g/dl ) particularly when we consider that the
Nutritional aspects
mean dialysis age of the patients of this study was 58 months. It is well known that protein and calorie intake is
The clinical impact of membranes on the lipid profile related to the survival of patients on substitutive of dialysis patients is still debatable; in this respect, treatment.
the role of the underlying disease, diet, dialysate buffer Gutierrez et al. [17] found that sham dialysis with a and heparins should also be taken into account. cellulose membrane on healthy volunteers was related
In conclusion, our previous considerations conto the loss of amino acids, thus indicating protein cerning cardiovascular stability also apply to the nutricatabolism. Protein catabolism was less detectable tional aspect; thus future trials should be designed to using synthetic membranes, such as AN69, polysulfone involve a sicker patient population with a high prevalor cellulose acetate. However, these findings have not ence of malnutrition in order to provide statistical been confirmed in uraemic patients [18] .
Moreover, it has been suggested, although using power.
Van Ypersele de Strihou et al. [27] , retrospectively Infections analysed patients treated with different membranes, and found a lower incidence of cystic bone lesions in Vanholder et al.
[21] found a reduction in the incidence those treated with a synthetic membrane (AN69) than of sepsis in patients treated with a polysulfone memin those treated with a cuprophane membrane. One of brane vs patients treated with a cuprophane membrane.
the most interesting findings of this study was the However, this is a very provocative paper involving important role of age in increasing the incidence of only 16 patients with a very short follow-up (20 weeks).
cystic bone lesions in both treatments. Locatelli et al. [10] were unable to confirm this observaBonomini et al.
[28] retrospectively analysed 122 tion. However, the possibility of a lower mortality rate patients divided into two groups on the basis of the due to infection being achieved with the use of semisyndialysis membrane used (cellulose or synthetic), and thetic or synthetic membranes has recently been did not find any difference between the membranes in reported in a USRDS case-mix adequacy study analysis terms of survival and general or b 2 -microglobulinby Bloembergen et al. [22] . related morbidity. Kuchle et al. [29, 30] conducted a trial involving 20
Anaemia patients who had been treated previously with lowflux cuprophane HD membranes and who were ranKobayashi et al. [23] found that only highly permeable domized to continue the same haemodialysis regimen biocompatible membranes are able to remove high-or to receive haemodialysis treatment with high-flux molecular-mass substances that inhibit erythropoiesis, polysulfone membranes. After a 6-year follow up [29] , thus stressing the importance of permeability.
no clinical signs of dialysis-associated amyloidosis were In a prospective randomized study of 135 patients, found in any of the 10 patients dialysed using polysulIfudu et al. [24] reported that increasing the intensity fone membranes, whereas eight of the patients dialysed of dialysis in patients receiving inadequate dialysis led with cuprophane membranes had carpal tunnel synto a significant increase in the response to erythropoie-drome and/or osteoarticular lesions. After 8 years of tin. However, the increase in dialysis dose was obtained follow-up [30] clinical signs of dialysis-associated amylby using more permeable and biocompatible mem-oidosis were found in two of the patients dialysed branes (high-flux polysulfone), which at least suggests using polysulfone membranes. Moreover, the serum a possibly additive effect of biocompatibility and/or levels of b 2 -microglobulin were significantly reduced permeability on the correction of anaemia.
in the patients treated with high-flux polysulfone A prospective randomized controlled trial by membranes. Locatelli et al. aimed at assessing the role of the flux Hakim et al. [14] found that the use of biocompatible of membrane on response to erythropoietin is ongoing. membranes over a period of 18 months, even in the low-flux configuration ( low-flux polymethylmetacrylate), was associated with a significantly slower increase b 2 -Microglobulin removal in plasma b 2 -microglobulin. However, the authors themselves underlined the fact that there were no The aspect of b 2 -microglobulin dialysis-related amyl-significant differences in the actual level of b 2 -microoidosis is very important and it should be stressed that globulin (and residual renal function) between the two the prevalence of clinical signs of b 2 -microglobulin groups during the follow-up period. amyloidosis is very low in comparison with the histoLocatelli et al. [10] found a significant decrease in logical prevalence. Thus the clinical symptoms of b 2 -pre-dialysis plasma b 2 -microglobulin levels in high-flux microglobulin amyloidosis should be considered to be dialysis and haemodiafiltration (both using a high-flux the tip of the iceberg of dialysis-related amyloidosis.
polysulfone membrane) compared with cuprophan and In a prospective post-mortem study [1] the prevallow-flux polysulfone membranes. ence of carpal tunnel syndrome surgery or of radioloIt is well known that carpal tunnel syndrome gical signs of b 2 -microglobulin amyloidosis was 2-4% and b 2 -microglobulin dialysis-associated amyloidotic respectively, compared with a histological prevalence arthropathy are present in a very large percentage of, of 48% after a mean period on haemodialysis of 47 especially, older patients on long-term regular dialysis months, which reached 100% after more than 13 years treatment and that this greatly affects their quality of on haemodialysis. It is worth noting that a much life [31] . Using data from the Lombardy Registry, higher prevalence of amyloidotic b 2 -microglobulin Locatelli et al.
[32] carried out a historical prospective deposits in the periosteum of the iliac crest have been study of 6440 patients who had started renal replacefound in chronic haemodialysed patients with femoral ment therapy between 1983 and 1995. The authors neck fractures [25] , further supporting the clinical found that the relative risk for carpal tunnel syndrome relevance of the problem.
surgery (evaluated as a parameter of morbidity) was It is well known that no relationship between pre-44% lower in the patients treated with haemodiadialysis plasma b 2 -microglobulin levels and dialysisfiltration or haemofiltration (RR=0.56; 95% CI: related amyloidosis has been found [26 ] . However, it 0.34-0.92; P=0.02) than in those treated with standard is difficult to find other parameters suitable for large clinical trials.
haemodialysis, thus supporting the importance of convective treatment in reducing morbidity from b 2 -tuted cellulose membranes. However, the authors microglobulin deposition. themselves stressed that more definitive studies are needed before a cause and effect relationship can be proven. Since synthetic and (to a much lesser extent)
Morbidity and mortality
modified cellulose membranes have a higher clearance of middle molecules, it must be explained whether the Chanard et al. [6 ] reported that, compared with cupro-effect may be due to differences in the clearance of phan, the use of a biocompatible membrane (PAN ) such solutes. was related to positive effects on rehabilitation, the Locatelli et al. [32] , in a study of 6440 patients hospitalization index and the number of days in hos-treated in Lombardy between 1983 and 1995, found pital. Although the incidence of hypotension, vomiting, that the relative risk for mortality was not significantly cramps and headaches was notably less for the patients lower in convective treatments (RR=0.90). dialysed using the AN69 membrane, there was no real difference in mortality between the two groups.
Churchill et al.
[33] performed a randomized, prospective, double-blind, cross-over study on 21 patients Conclusion comparing low-flux cellulose acetate and high-flux cellulose diacetate membranes to verify the effect of high-It is very difficult to ascribe the positive effects found flux haemodialysis on cardiac structure and function. in several non-randomized retrospective studies entirely The modest improvements in estimates of systolic to the different modalities because of the many confunction during the 4-month follow-up with each mem-founders (i.e. biocompatibility of the membranes and brane suggest a cardiac advantage in high-flux dialysis, permeability), although some very sophisticated statistthe clinical impact of which requires further study. ical methods have been used in some studies. It is Hornberger et al. [34] performed a retrospective important to stress that, when there is no difference study comparing 146 patients on standard haemodia-between treatment groups, one does not accept the lysis treatment with 107 patients on high-flux haemo-null hypothesis but rather fails to reject it. In other dialysis. The relative risk of mortality on high-flux words, if the data do not show any between-treatment haemodialysis was 0.24 (95% CI: 0.12-0.49), deriving difference, this does not imply equivalence but rather from 69 deaths in the standard dialysis group vs 11 that there is not enough evidence to conclude that one among the patients on high-flux haemodialysis.
treatment is better than the others. Therefore, future Locatelli et al. [10] did not find any difference in trials should involve a sicker patient population in mortality and morbidity among the four randomized order to achieve statistical power. patient groups during the 24-month follow-up, but the Epidemiological studies suggest that semisynthetic trial was not designed to evaluate the possible differand synthetic membranes and flux seem to reduce ence in morbidity and mortality. Thus the observation morbidity and mortality in dialysis patients. period did not allow any evaluation of a possible
The results of the published prospective, randomdifference in long-term morbidity and mortality.
ized, controlled trials are conflicting [37] , and only the In a retrospective analysis of 715 patients, Woods results of other trials with a long follow-up (for [35] identified two groups: 252 patients treated exclusexample the HEMO study [38, 39] can better clarify ively with low-flux polysulfone and 463 patients treated the effect of different treatment modalities on the for at least 3 months, and up to 5 years, with highmorbidity and mortality of patients on chronic renal flux polysulfone. The patients treated with high-flux replacement therapy. In particular, it must be explained polysulfone experienced lower mortality (21 vs 36 per whether the effect is based only on the biocompatibility 1000 years; P<0.01) and had a better probability of of the membrane per se or on differences in the survival at 5 years (90 vs 60%; P=0.029). In a Cox clearance of medium-sized molecules, or more generproportional hazards model, high-flux dialysis was ally on the flux of the membrane. However, these trials associated with a 70% reduction in death risk when are very difficult to conduct because of the need for compared with low-flux dialysis. The author suggests randomization and the high drop-out rate of patients. that the higher clearance of larger molecular species of putative uraemic toxins achieved with high-flux dialysis Note added in proof: Two important papers have been confers a survival advantage that is independent of published while this paper was in preparation: any membrane biocompatibility effect.
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